MicroRNA 1299 (miR-1299)

MicroRNA 1299 (miR-1299) is a small, evolutionarily conserved, endogenous, noncoding RNA belonging to the family of microRNAs. It acts primarily as a **tumor suppressor** in various human cancers, where it is typically downregulated compared to normal tissue. miR-1299 functions by binding to complementary sequences within the 3′ untranslated regions of target messenger RNAs (such as CDK6, CDK8, STAT3, MMPs, and NOTCH3), thereby inhibiting their translation or triggering their degradation. Through these interactions, miR-1299 regulates critical biological processes including cell proliferation, cell cycle progression, apoptosis, migration, and invasion. Its downregulation is associated with cancer progression, chemoresistance, and poor prognosis, highlighting its value as a candidate **biomarker** and a putative therapeutic target in oncology. There are no small molecule or approved drugs directly targeting miR-1299, but its modulation can alter sensitivity to anti-cancer agents like paclitaxel. Research on miR-1299 in non-cancer diseases is nascent, and its therapeutic application faces general challenges inherent to microRNA-based interventions[1][2]. **Note:** miR-1299 is not a protein, receptor, enzyme, ion channel, transporter, or classical drug target, but it is a validated therapeutic target and biomarker in cancer biology due to its regulatory control over gene expression impacting disease pathways[1][2].

Other names

hsa-miR-1299MIR1299MIRN1299hsa-mir-1299

Indirect: miR-1299 acts by downregulating or degrading target mRNA (e.g., CDK6, CDK8, STAT3, MMPs, NOTCH3), leading to suppression of protein translation required for proliferation and survival. Increases sensitivity to chemotherapy (e.g., paclitaxel) by targeting pathways involved in drug resistance.